动物造模,肺癌人源性肿瘤组织异种移植 z-bio 2021-05-10 1314

　　OBJECTIVE: To establish a nude mouse model of patient-derived tumor xenograft (PDX) of human-derived lung cancer tumor tissue to detect changes in tissue morphology, p63, napsin A, p63, napsin A and primary lung tissue specimens. Cancer tissue specimens and third-generation (F3) PDX model tissue specimens. The expression of TTF-1 is different.

　　Methods: Twelve fresh surgical specimens of lung cancer were taken, subcutaneously transplanted to establish a nude mouse PDX model, HE staining was used to compare the structure and cell morphology of primary and transplanted tumor tissues, and immunohistochemical methods were used to detect primary tumors. The expression levels of p63, napins A and TTF-1 between tissue samples of different generations and tissue samples of F3 generation. Microscopic observation.

　　Result: We successfully established 5 PDX models, 4 lung squamous cell carcinomas and 1 lung adenocarcinoma inherited in the third generation. The PDX model and the patient's primary tumor have the same histological characteristics and arrangement; in lung squamous cell carcinoma patients and their PDX model cancer cells, the positive expression rates of p63 are 84.3% and 96%, respectively. There is no significant difference in lung adenocarcinoma (P\→0.05), and the expression is negative. The positive expression rates of APSA A in lung adenocarcinoma and PDXF3 cancer cells were 66% and 72.4%, respectively, and there was no significant difference between the two (P\→0.05). The positive expression rates of TTF-1 in lung adenocarcinoma and its PDXF3 cancer cells were 91% and 85%, respectively, and there was no significant difference between the two (P\→0.05). Both apsinA and TTF-1 are negatively expressed in lung squamous cell carcinoma.

　　Conclusion: The lung cancer PDX model established in our laboratory basically retains some of the histological characteristics of the primary tumor. It is used for individual screening and evaluation of preclinical effects and identification of biomarkers, providing effective R&D resources.